Glucotrack Advances Continuous Blood Glucose Monitor with First Human Trial Success
Glucotrack has completed a groundbreaking first-in-human study of its intravascular continuous blood glucose monitor, demonstrating safety and technical feasibility for insulin-dependent diabetes patients. The successful trial paves the way for a comprehensive long-term clinical evaluation.
Medical technology company Glucotrack has achieved a significant milestone in diabetes management with its first-in-human study of an innovative continuous blood glucose monitor (CBGM). The study, conducted at InCor Hospital in São Paulo, Brazil, successfully tested an intravascular glucose monitoring system designed to address critical limitations of traditional continuous glucose monitors.
The research involved six adult participants with insulin-dependent diabetes, focusing on evaluating the safety and performance of the implantable device. Key results were promising: the study achieved a 99% data capture rate with a Mean Absolute Relative Difference of 6.7% when compared to standard fingerstick glucose measurements.
Unlike existing continuous glucose monitors that measure interstitial fluid, Glucotrack's device directly monitors blood glucose levels, potentially offering more accurate and real-time readings. The system is designed to be fully implantable, discreet, and capable of functioning for multiple years with minimal recalibration.
The successful first-in-human trial represents a critical advancement for diabetes management technology. By demonstrating the device's safety and initial performance, Glucotrack has positioned itself to launch a comprehensive long-term clinical trial. This upcoming study will enroll up to 30 participants and assess the commercial version of the CBGM system over an initial one-year period.
With approximately 38.4 million Americans living with diabetes, and 1.7 million adults using insulin, this technology could significantly improve patient monitoring and potentially reduce the complications associated with glucose level management. The research offers hope for more seamless, accurate, and less invasive diabetes tracking.